anti-SNRPE (SNRPE) Antikörper

Bezeichnung:: anti-Small Nuclear Ribonucleoprotein Polypeptide E Antikörper (SNRPE)

Auf www.antikoerper-online.de finden Sie aktuell 160 Small Nuclear Ribonucleoprotein Polypeptide E (SNRPE) Antikörper von 22 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen SNRPE Proteine (12) und SNRPE Kits (11) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 197 SNRPE Produkte verfügbar.

Synonyme:: 9930012E13Rik, AA120551, AA387315, AA473386, AL022645, b-raf, B-RAF1, Braf-2, BRAF1, Braf2, C76690, C87398, C230098H17, D6Ertd631e, HYPT11, NS7, RAFB1, sm-e, SmE, snRNP-E, zgc:56682

Alle Antikörper anzeigen	Gen	GeneID	UniProt
	SNRPE	673	P15056
	SNRPE	109880	P28028
Alle Spezies anzeigen Weitere Synonyme anzeigen

Meistgesuchte Reaktivitäten zu anti-SNRPE (SNRPE) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human SNRPE Antikörper:

anti-Mouse (Murine) SNRPE Antikörper:

Alle verfügbaren anti-SNRPE Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Verknüpfte Pathways mit anti-SNRPE Antikörper

Weitere Produktkategorien zu SNRPE Antikörper

Am meisten referenzierte anti-SNRPE Antikörper

Human Polyclonal SNRPE Primary Antibody für IHC, IHC (p) - ABIN4282574 : Beltran-Sastre, Benisty, Burnier, Berger, Serrano, Kiel: Tuneable endogenous mammalian target complementation via multiplexed plasmid-based recombineering. in Scientific reports 2015 (PubMed)

Weitere Antikörper gegen SNRPE Interaktionspartner

Human Small Nuclear Ribonucleoprotein Polypeptide E (SNRPE) Interaktionspartner

genetic association/nutrigenomic studies in population in Seoul, Republic of Korea: Data suggest that (1) relatively low iodine intake and (2) more than excessive iodine intake are significant risk factors for occurrence of BRAF (zeige BRAF Antikörper) mutations in thyroid gland and may be risk factors for development of PTC (zeige F9 Antikörper) (papillary thyroid cancer) in iodine-replete area.
The BRAF (zeige BRAF Antikörper) gene has been reported to be mutated in some human cancers. The BRAF (zeige BRAF Antikörper) mutations have been implicated in ameloblastoma.
Children with Langerhans cell histiocytosis (LCH) tend to have a high overall survival rate and a high incidence rate of BRAF (zeige BRAF Antikörper)-V600E mutation.
BRAF (zeige BRAF Antikörper) mutations more frequently affected individuals younger than 61 with phototype II. In contrast, NRAS (zeige NRAS Antikörper) mutations were more frequent in phototype III cases. Mutations of both genes were more frequent in cases with satellitosis in the first melanoma, and in cases with ulceration in the subsequent lesions.
Identification of KRAS/NRAS/BRAF (zeige BRAF Antikörper) mutation status is crucial to predict the therapeutic effect and determine individual therapeutic strategies for patients with colorectal cancer.
we did not observe GNAS (zeige GNAS Antikörper) or BRAF (zeige BRAF Antikörper) mutations in urachal adenocarcinomas
Study finds infrequent BRAF (zeige BRAF Antikörper) alterations but enriched FGFR (zeige FGFR2 Antikörper) alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF (zeige BRAF Antikörper) and FGFR (zeige FGFR2 Antikörper) alterations and a significant association of FGFR (zeige FGFR2 Antikörper) alterations with age and tumor location were noted.
a low frequency of BRAF or KRAS mutation in Chinese patients with low-grade serous carcinoma of the ovary
genetic association studies in population in China: Data suggest that, in patients with unilateral papillary thyroid carcinoma, a mutation in BRAF (zeige BRAF Antikörper) (V600E) plus multi-focality are both independently and synergically associated with CLNM (central lymph node metastasis) in the population studied.
RHEB (zeige RHEB Antikörper) Y35N expressing cells undergo cancer transformation due to decreased interaction between RHEB (zeige RHEB Antikörper) and BRAF (zeige BRAF Antikörper) resulting in overactive RAF (zeige RAF1 Antikörper)/MEK (zeige MAP2K1 Antikörper)/ERK (zeige EPHB2 Antikörper) signaling. Taken together with the previously established function of RHEB (zeige RHEB Antikörper) to activate mTORC1 signaling, it appears that RHEB (zeige RHEB Antikörper) performs a dual function; one is to suppress the RAF (zeige RAF1 Antikörper)/MEK (zeige MAP2K1 Antikörper)/ERK (zeige EPHB2 Antikörper) signaling and the other is to activate mTORC1 signaling.

Mouse (Murine) Small Nuclear Ribonucleoprotein Polypeptide E (SNRPE) Interaktionspartner

mosaic expression of BRAF (zeige BRAF Antikörper)(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (zeige CDX2 Antikörper)(Null)/BRAF (zeige BRAF Antikörper)(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF (zeige BRAF Antikörper)(V600E) potently interacted with CDX2 (zeige CDX2 Antikörper) silencing to alter gene expression. Like human serrated lesions, CDX2 (zeige CDX2 Antikörper)(Null)/BRAF (zeige BRAF Antikörper)(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf (zeige BRAF Antikörper)(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF (zeige BRAF Antikörper)(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF (zeige BRAF Antikörper)-inactivating mutations are initiating events in lung oncogenesis
TTM (zeige SLITRK1 Antikörper) reduces copper levels and MAPK (zeige MAPK1 Antikörper) signaling, thereby inhibiting BRAF (zeige BRAF Antikörper)(V600E)-driven melanoma tumor growth.
BRAF (zeige BRAF Antikörper) and ROKalpha (zeige ROCK2 Antikörper) form independent RAF1 (zeige RAF1 Antikörper) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (zeige EGF Antikörper)).
Braf (zeige BRAF Antikörper)(V600E) expression, coupled with simultaneous p53 (zeige TP53 Antikörper) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF (zeige BRAF Antikörper)(V600E) in metastasis.
Mechanistically, BRAF (zeige BRAF Antikörper) and RAF1 (zeige RAF1 Antikörper) operate independently to balance MAPK (zeige MAPK1 Antikörper) signaling: BRAF (zeige BRAF Antikörper) promotes ERK (zeige EPHB2 Antikörper) activation, while RAF1 (zeige RAF1 Antikörper) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF (zeige BRAF Antikörper) interacts and phosphorylates PAX3 (zeige PAX3 Antikörper).
Using a conditional allele for Braf (zeige BRAF Antikörper)(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf (zeige BRAF Antikörper)(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.

SNRPE Antigen-Profil

Beschreibung des Gens

This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.

Alternative names and synonyms associated with SNRPE

B-Raf proto-oncogene, serine/threonine kinase (BRAF) Antikörper
small nuclear ribonucleoprotein polypeptide E (SNRPE) Antikörper
small nuclear ribonucleoprotein polypeptide E L homeolog (snrpe.L) Antikörper
Braf transforming gene (Braf) Antikörper
small nuclear ribonucleoprotein E (Snrpe) Antikörper
small nuclear ribonucleoprotein polypeptide E (snrpe) Antikörper
small nuclear ribonucleoprotein polypeptide E (Snrpe) Antikörper

9930012E13Rik Antikörper
AA120551 Antikörper
AA387315 Antikörper
AA473386 Antikörper
AL022645 Antikörper
b-raf Antikörper
B-RAF1 Antikörper
Braf-2 Antikörper
BRAF1 Antikörper
Braf2 Antikörper
C76690 Antikörper
C87398 Antikörper
C230098H17 Antikörper
D6Ertd631e Antikörper
HYPT11 Antikörper
NS7 Antikörper
RAFB1 Antikörper
sm-e Antikörper
SmE Antikörper
snRNP-E Antikörper
zgc:56682 Antikörper

Bezeichner auf Proteinebene für SNRPE

94 kDa B-raf protein , B-Raf proto-oncogene serine/threonine-protein kinase (p94) , murine sarcoma viral (v-raf) oncogene homolog B1 , proto-oncogene B-Raf , serine/threonine-protein kinase B-raf , v-raf murine sarcoma viral oncogene homolog B1 , sm protein E , small nuclear ribonucleoprotein E , snRNP-E , small nuclear ribonucleoprotein polypeptide E , SmE protein , sm-E , smE

GENE ID	SPEZIES
673	Homo sapiens
6635	Homo sapiens
443996	Xenopus laevis
478934	Canis lupus familiaris
741566	Pan troglodytes
109880	Mus musculus
396180	Gallus gallus
100038330	Sus scrofa
531493	Bos taurus
20643	Mus musculus
393979	Danio rerio
100724868	Cavia porcellus

Ausgewählte Anbieter für anti-SNRPE (SNRPE) Antikörper

Haben Sie etwas anderes gesucht?

Telefon:	+1 877 302 8632
Fax:	+1 888 205 9894 (Toll-free)
E-Mail:	orders@antikoerper-online.de

Show all anti-Small Nuclear Ribonucleoprotein Polypeptide E (SNRPE) Antikörper with Pubmed References

Human Small Nuclear Ribonucleoprotein Polypeptide E (SNRPE) Interaktionspartner

Mouse (Murine) Small Nuclear Ribonucleoprotein Polypeptide E (SNRPE) Interaktionspartner

Beschreibung des Gens

Alternative names and synonyms associated with SNRPE

Bezeichner auf Proteinebene für SNRPE